Slamon and colleagues: trastuzumab plus chemotherapy in HER2-positive metastatic breast cancer

What changed

HER2-targeted antibody benefit was demonstrated in a defined metastatic treatment setting.

Scientific scope

Exact 12-author 2001 trial, its patients/regimens/follow-up; adjuvant trials and later therapy separate.

Evidence

The linked sources identify this contribution and its scope. WRS has not independently reconstructed the scientific claims. The record is the exact 2001 NEJM trial and its enrolled population, regimens and follow-up. HER2 biology, antibody engineering, adjuvant trials, later regimens and population-wide impact remain separate.

Contributors

• The named authors listed in the linked research record · SCIENCE: Complete source byline retained in the research record; this collective display does not merge person identities or measure labor shares.

• Slamon et al., trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer
• Crossref record for trastuzumab metastatic-breast-cancer trial

Provisional WRS assessment, edition 2026-10-16.1. Independent expert calibration is pending. This grade does not certify correctness or assign ownership.

Full scientific record · Browse contribution grades · Request a correction